Abstract
Target Population: Infectious diseases specialists, as well as physicians, nurses, and public health workers who care for children Sponsoring Organization: CDC Type: Recommendations of the Advisory Committee on Immunization Practices. This report is consistent with recommendations by the American Academy of Pediatrics Committee on Infectious Diseases. Key Points: In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (Prevnar [PCV7]) was licensed for infants and young children in the U.S. Subsequently, the rates of pneumococcal sepsis and meningitis in children fell, but infections caused by nonvaccine serotypes have persisted, and the prevalence of nonvaccine serotypes may be increasing. On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
